Protara Therapeutics Q3 2026 earnings

TARA · 2026-11-06 08:05 BMO ET · 8-K on SEC · 10-Q on SEC

Net loss widened to $21.7M in Q3 driven by higher operating expenses, partially offset by lower interest income.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)-$0.35+12.9%+2.9%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $23,154 (+56.9% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and investments$143M$162M—-$19M
Weighted-average shares outstanding62.85M61.01M42.27M+3.0%

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story Loss per share widened YoY due to higher operating expenses and share count, despite a slight QoQ improvement.
  • One-off check not stated in the 8-K

The good

  • Cash balance of $143M supports operations into 2028
  • Completed enrollment of THRIVE-3 Phase 2b dosing cohort

The bad

  • Net loss widened to $21.7M in Q3
  • Interest income declined 11.6% QoQ

The ugly

  • none

Open questions

  • What caused the decline in interest and investment income?
  • Why did R&D expenses increase 75.3% YoY?
Full release

Protara Therapeutics (TARA) earnings release, November 6, 2026

Protara Therapeutics, Inc. (TARA) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Protara

Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026

Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q’2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027

Completed enrollment of THRIVE-3 Phase 2b dosing cohort evaluating IV Choline Chloride in patients dependent on long-term parenteral support; remain on track to report interim results by year-end 2026

Entered into an asset purchase agreement with Novex Innovations for TARA-002 manufacturing-related assets for $8.75 million

Cash, cash equivalents and investments of approximately $143 million as of September 30, 2026, expected to support planned operations into 2028

NEW

YORK, Novemb er 6, 2026 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.

“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful

2027,” said Jesse Shefferman, Chief Executive Officer at Protara Therapeutics. “TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients. Following quarter end, we also entered into a purchase agreement for TARA-002 manufacturing-related assets from Novex Innovations, LLC, our clinical supply partner since 2019. We are excited to bring this manufacturing capability in-house as we advance our late-stage clinical trials and prepare to launch TARA-002 in lymphatic malformations (LMs) and NMIBC.”

Mr.

Shefferman added, “Turning to our rare disease pipeline, we now expect to complete enrollment of the registrational STARBORN-1 trial of TARA-002 in LMs early in the first quarter of 2027. Supported by the program’s Breakthrough Therapy designation, we remain on track to initiate our rolling Biologics License Application (BLA) submission in the second half of 2027. We also completed enrollment of the Phase 2b portion of the THRIVE-3 trial of IV Choline Chloride and look forward to reporting interim results by the end of this year.”

Recent

Progress and Highlights

TARA-002 in NMIBC

TARA-002 in LMs

IV

Choline Chloride for Patients on Parenteral Support (PS)

Corporate

Update²

Third

Quarter 2026 Financial Results

About

TARA-002

TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric

Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes with a mechanism of action that includes the activation of innate and adaptive immune pathways within the bladder wall. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with the release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-6, IL-10 and IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.

TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd.

About

Non-Muscle Invasive Bladder Cancer

Bladder cancer is the sixth most common cancer in the United States, with non-muscle invasive bladder cancer (NMIBC) representing approximately

80% of bladder cancer diagnoses, or approximately 65,000 patients in the U.S. each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle. Patients suffering from high-grade, high-risk NMIBC face high rates of disease recurrence and are potentially subject to full removal of the bladder (cystectomy).³

About

Lymphatic Malformations

Lymphatic

Malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Protara’s focus is on macrocystic and mixed cystic LMs, for which there are no currently approved therapies. More than 50% of LMs are detected at birth and 90% are diagnosed before the age of three years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels and lymphatics; recurrent infection; and cosmetic and other functional disabilities. TARA-002 has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA for the treatment of

LMs.

About

IV Choline Chloride for Patients on Parenteral Support

IV

Choline Chloride is an investigational, intravenous phospholipid substrate replacement therapy in development for patients receiving... (truncated) phospholipids that are critical for healthy liver function and play an important role in modulating gene expression, cell membrane signaling, brain development and neurotransmission, muscle function and bone health. There are currently no available PS formulations containing choline. IV Choline Chloride has the potential to become the first FDA approved IV choline formulation for PS patients. It has been granted Orphan Drug designation by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition and has been granted Fast Track designation as a source of choline when oral or enteral nutrition is not possible, insufficient or contraindicated.

The U.S. Patent and Trademark

Office has issued Protara a U.S. patent claiming a choline composition and a U.S. patent claiming a method of treating choline deficiency with a choline composition, each with a term expiring in 2041.

About

Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

For more information, visit www.protaratx.com.

Forward-Looking

Statements

Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,”

“believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,”

“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”

Financial statements

Income Statement

For the Three Months Ended September 30, — (in thousands, except share and per share data)

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Operating expenses:
Research and development16,8059,59147,32229,509
General and administrative6,3495,16918,78515,961
Total operating expenses23,15414,76066,10745,470
Income (Loss) from operations-23,154-14,760-66,107-45,470
Other income (expense), net:
Interest and investment income (expense)1,4661,5024,9694,857
Other income (expense)481
Other income (expense), net1,4661,5024,9695,338
Net income (loss)-21,688-13,258-61,138-40,132
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities-18766-640141
Other comprehensive income (loss)-18766-640141
Comprehensive income (loss)-21,875-13,192-61,778-39,991
Net income (loss) per share attributable to common stockholders, basic and diluted-0.35-0.31-1.01-0.96
Weighted-average shares outstanding, basic and diluted62,850,74342,272,10460,484,90541,756,028

Balance Sheet

(in thousands, except share and per share data)

As of – September 30, 2026As of – December 31, 2025
Current assets:
Cash and cash equivalents25,15049,657
Marketable debt securities101,900105,897
Prepaid expenses and other current assets2,6173,950
Total current assets129,667159,504
Restricted cash, non-current745745
Marketable debt securities, non-current16,03142,336
Property and equipment, net1,581759
Operating lease right-of-use asset2,3083,174
Other assets6,2092,950
Total assets156,541209,468
Current liabilities:
Accounts payable4,8623,468
Accrued expenses and other current liabilities8,2206,229
Operating lease liability1,3091,242
Total current liabilities14,39110,939
Operating lease liability, non-current1,1272,117
Total liabilities15,51813,056
Common stock, $0.001 par value, 200,000,000 and 100,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively:
Common stock, 59,967,669 and 53,587,260 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively6054
Additional paid-in capital505,070498,687
Accumulated deficit-363,557-302,419
Accumulated other comprehensive income (loss)-55090
Total stockholders’ equity141,023196,412
Total liabilities and stockholders’ equity156,541209,468

“might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara’s financial position; statements regarding the anticipated safety or efficacy of Protara’s product candidates; and Protara’s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general U.S. and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date.

Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.⁴

PROTARA

THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed

Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)⁵

PROTARA

THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share data)⁶

Company

Contact:

Justine O’Malley

Protara Therapeutics

Justine.OMalley@protaratx.com

646-817-2836⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Protara Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.